Pigmented (melanotic) schwannomas of the spinal canal

Lowman, Robert M.; LiVolsi, Virginia A.

doi:10.1002/1097-0142(19800715)46:2<391::aid-cncr2820460230>3.0.co;2-c

Cited by 54 publications

(15 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[24] These tumors most frequently occur in the cervical and thoracic spine (46%). [521] Spinal melanotic schwannomas are usually benign,[1671012131718202627] but two cases of psammomatous spinal melanotic schwannomas have been reported. [1117]…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Malignant psammomatous melanotic schwannoma of the spine: A component of Carney complex

Shields¹,

Glassman²,

Raque³

et al. 2011

Surg Neurol Int

View full text Add to dashboard Cite

Background:Psammomatous melanotic schwannomas (PMS) of the spine may be a component of the Carney complex in 50% of cases and is inherited in an autosomal dominant manner. Most PMS are benign and frequently associated with lentiginous pigmentation; cardiac, cutaneous, or breast myxomas; endocrine overactivity; and cutaneous blue nevi. These tumors are characterized by melanin containing cells having ultrastructural characteristics of Schwann cells.Case Description:Two patients had spinal PMS that were surgically resected with adjacent local radiotherapy, followed by local recurrence and metastasis. The aggressive nature of this tumor is reported.Conclusion:Spinal PMS are rarely malignant with local recurrence and distal metastases. Inquiry into the patient's and family members’ hereditary background for the Carney complex is important to avoid overlooking potential lethal associated abnormalities.

show abstract

Section: Discussionmentioning

confidence: 99%

“…[1213] Without complete resection, local tumor recurrence or malignant transformation and remote metastasis may occur. [2151726] Aggressive local tumor recurrence following incomplete resection of the PMS occurred in both of our patients.…”

Section: Discussionmentioning

confidence: 99%

Malignant psammomatous melanotic schwannoma of the spine: A component of Carney complex

Shields¹,

Glassman²,

Raque³

et al. 2011

Surg Neurol Int

View full text Add to dashboard Cite

show abstract

“…Recurrence and metastases are observed 20 years after diagnosis. Furthermore, intracranial topography presents a higher risk [789]. The main site of metastasis is the lung.…”

Section: Discussionmentioning

confidence: 99%

Intracranial Melanotic Schwannomas: Rare and Distinctive Tumors to Know Due to their Risk of Recurrence and Metastases

Collart

Vandeponseele

Bosschaert

2018

Journal of the Belgian Society of Radiology

View full text Add to dashboard Cite

Melanotic schwannomas are rare nerve sheath tumors that differentiate themselves from classical schwannomas by harboring melanin-producing cells. Intracranial localizations are uncommon, especially on the Gasserian ganglion. We performed a literature review, presenting imaging characteristics, differential diagnosis, and immunohistochemical features for identification. These tumors carry the risk of recurrence and metastases. The prognosis is uncertain. We discuss recommendations for diagnosis and treatment.

show abstract

“…Neurofibromatosis I, or Von Recklinghausen's disease, is a genetic disease that affects one in every 2,500 to 3,000 live births (Lowman and LiVolsi 1980). It is an autosomal dominant inherited disorder with a high rate of penetrance (Enzinger and Weiss 1995).…”

Section: Discussionmentioning

confidence: 99%

Diffuse Large B-cell Lymphoma Arising in a Patient with Neurofibromatosis Type I and in a Patient with Neurofibromatosis Type II

Dohi

Hatori

Ichinohasama

et al. 2006

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

We experienced two unusual cases of diffuse large B-cell lymphoma (DLBCL), which occurred in a patient with neurofibromatosis type I and a patient with neurofibromatosis type II. B-cell lymphoma is one of the most common phenotypic subgroups of malignant lymphoma. Neurofibromatosis I is characterized by café-au-lait spots and neurofibromas. Neurofibromatosis II typically consists of bilateral schwannomas of the acoustic nerve. Malignant lymphomas rarely coexist with neurofibromatosis I, and no coexistence with neurofibromatosis II has been reported. The patient with neurofibromatosis I was a 50-year-old Japanese woman, clinically manifesting von Recklinghausen's disease since infancy, who noticed an egg-sized tumor in her shoulder. The patient with neurofibromatosis II was a 39-year-old Japanese man who noticed multiple soft tissue tumors in his neck, buttock, and elbow. Biopsied materials from both cases were examined by multiparameter methods, including flow cytometry. Flow cytometry revealed large-scale cells to be tumor cells, and they were positive for CD19, CD20, and CD22. Both patients received chemotherapy, and the tumors disappeared. The patient with neurofibromatosis I was alive without recurrence at 4 years after treatment, while the patient with neurofibromatosis II died of recurrence. To the best of our knowledge, this is the first case of malignant lymphoma arising in a neurofibromatosis II patient. As for neurofibromatosis I, there were some reports about occurrence of malignant lymphoma. It is important to be aware of possibility of association of malignant tumors not only of the nervous system but also of unrelated to the nervous system when tumors appear in neurofibromatosis patients. malignant lymphoma; neurofibromatosis; flow cytometry; immunohistochemistry

show abstract

Pigmented (melanotic) schwannomas of the spinal canal

Cited by 54 publications

References 20 publications

Malignant psammomatous melanotic schwannoma of the spine: A component of Carney complex

Malignant psammomatous melanotic schwannoma of the spine: A component of Carney complex

Intracranial Melanotic Schwannomas: Rare and Distinctive Tumors to Know Due to their Risk of Recurrence and Metastases

Diffuse Large B-cell Lymphoma Arising in a Patient with Neurofibromatosis Type I and in a Patient with Neurofibromatosis Type II

Contact Info

Product

Resources

About